Abstract CT063: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies (NCT04886622)

耐火材料(行星科学) 医学 内科学 肿瘤科 实体瘤 相(物质) 癌症 化学 材料科学 冶金 有机化学
作者
Daruka Mahadevan,Minal Barve,Devalingam Mahalingam,Jay Parekh,Michael R. Kurman,James Strauss,Larry M. Tremaine,Robert Hromas,J A Sills,J. R. McCulloch,John Harkey,Stacy Suberg,Lisa J. Zimmerman,Guangrong Zheng,Daohong Zhou
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_2): CT063-CT063 被引量:1
标识
DOI:10.1158/1538-7445.am2025-ct063
摘要

Abstract Background: Upregulation of B-cell lymphoma extra-large (BCL-xL) has been implicated in cancer drug resistance and relapse. Small molecule inhibition of BCL-xL with navitoclax resulted in on-target, dose-limiting thrombocytopenia. DT2216 is the first BCL-xL PROTAC degrader that is more effective than navitoclax and has reduced platelet toxicity in preclinical models by selectively degrading BCL-xL via the VHL E3 ligase, which is minimally expressed in platelets. Methods: A dose escalation study using a 3 + 3 design. Doses ranged from 0.04 to 0.4 mg/kg IV twice weekly (BIW) in a 28-day cycle. Eligible subjects had solid tumors of any histology that had progressed on standard treatment and had measurable tumor by RECIST 1.1. Tumor assessment was at 8-week intervals. BCL-xL levels were measured in peripheral leukocytes by Western blotting. Results: 20 patients were enrolled with a median age of 60.5 yr; 60% female, 45% Hispanic, 15% African American and 55% had colorectal or pancreatic cancer. One dose limiting toxicity (DLT) was observed, a grade 4 thrombocytopenia at dose level 5 (0.32mg/kg), that resolved in 48 hours and patient remained on study. Patients remained on study for a median of 57 days (range 7 - 253). No patient discontinued due to treatment-related adverse events (TRAEs). The best response was stable disease (SD), observed in 20% of patients. The median duration of SD was 107 days. 19 of 20 patients completed the DLT period with one choosing to discontinue early to enter hospice. Reversible thrombocytopenia occurred in cycle 1 (C1) but not in C2, with most events noted at doses over 0.32mg/kg. The lowest platelet counts in C1 ranged from 24,000 to 297,000 with a median of 84,000. In all cases platelets recovered to >50,000 within 4 days and >75,000 in 1 week. There were no episodes of bleeding or TRAEs leading to death. Two patients required dose reduction due to repeated thrombocytopenia in C1, but both continued on study. Median overall survival was 7.9 months (95% CI 4.0 - NE). Plasma AUC of DT2216 was dose proportional, and all PK parameters were independent of dose, with the mean plasma t1/2 7.1 to 12.8 hrs, CL 4.1 to 7.9 mL/min/kg and Vdss <100 mL/kg. Patients receiving 0.4 mg/kg of DT2216 demonstrated rapid and sustained degradation of BCL-xL protein in peripheral leukocytes over the 72-96 hr dosing intervals with degradation fraction of >95%. Conclusions: Based on the rapid recovery of the transient thrombocytopenia that occurred only in the first cycle and the degradation of BCL-xL in peripheral leukocytes, the recommended phase 2 dose of DT2216 is 0.4 mg/kg IV BIW. Phase 2 clinical trials are being initiated for DT2216 in CTCL as monotherapy and in combination with chemotherapy in ovarian cancer and fibrolamellar HCC. Citation Format: Daruka Mahadevan, Minal Barve, Devalingam Mahalingam, Jay Parekh, Michael Kurman, James Strauss, Larry Tremaine, Robert Hromas, Joshua Sills, John McCulloch, John Harkey, Stacy Suberg, Lisa Zimmerman, Guangrong Zheng, Daohong Zhou. First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies (NCT04886622) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT063.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
keyan123完成签到,获得积分10
刚刚
1秒前
2秒前
2秒前
2秒前
胡歌完成签到,获得积分10
2秒前
七七发布了新的文献求助10
2秒前
嘤嘤怪发布了新的文献求助10
3秒前
Yxing完成签到,获得积分10
3秒前
Tsuki完成签到 ,获得积分10
3秒前
何桃完成签到,获得积分10
4秒前
魏伯安发布了新的文献求助10
4秒前
4秒前
sheryy发布了新的文献求助10
4秒前
chengsi发布了新的文献求助10
5秒前
5秒前
某叶完成签到 ,获得积分10
5秒前
5秒前
5秒前
路人甲乙丙丁完成签到,获得积分10
5秒前
1111完成签到,获得积分10
6秒前
7秒前
清辉影的应助被MADAO采纳,获得30
7秒前
ws发布了新的文献求助10
7秒前
7秒前
小y发布了新的文献求助10
8秒前
8秒前
LgY完成签到,获得积分10
8秒前
8秒前
不爱喝酒的应助被平常随阴采纳,获得10
9秒前
chen发布了新的文献求助10
9秒前
eeven的应助被初景采纳,获得10
10秒前
10秒前
Maestro_S的应助被研友_842M4n采纳,获得10
11秒前
qingxuan发布了新的文献求助10
11秒前
FossilGitter8发布了新的文献求助10
12秒前
冉123完成签到,获得积分20
12秒前
AquaticLily完成签到,获得积分10
12秒前
xixi完成签到 ,获得积分10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182014
求助须知:如何正确求助?哪些是违规求助? 9571728
关于积分的说明 21819478
捐赠科研通 7778441
什么是DOI,文献DOI怎么找? 3433580
关于科研通互助平台的介绍 2557781
邀请新用户注册赠送积分活动 2479640